Paola Francica

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining

Paola Francica, Merve Mutlu, Vincent A. Blomen et al. · Cell Reports · 2020 · 52 citations · Full text

Medicine, Cancer Biology, Oncology +17

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

Diego Dibitetto, Martin Liptay, Francesca Vivalda et al. · Nature Communications · 2024 · 42 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts

Elena Andreucci, Paola Francica, Antony Fearns et al. · Oncotarget · 2016 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition–Associated Checkpoint Abrogation

Kei Mikami, Michaela Medová, Lluís Nisa et al. · Molecular Cancer Research · 2015 · 32 citations

Medicine, Oncology, Radiation Oncology +17

The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants

Michaela Medová, Benoît Pochon, Bruno Streit et al. · Molecular Cancer Therapeutics · 2013 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17